BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37595344)

  • 1. Advancing the PD-L1 CPS test in metastatic TNBC: Insights from pathologists and findings from a nationwide survey.
    Fusco N; Ivanova M; Frascarelli C; Criscitiello C; Cerbelli B; Pignataro MG; Pernazza A; Sajjadi E; Venetis K; Cursano G; Pagni F; Di Bella C; Accardo M; Amato M; Amico P; Bartoli C; Bogina G; Bortesi L; Boldorini R; Bruno S; Cabibi D; Caruana P; Dainese E; De Camilli E; Dell'Anna V; Duda L; Emmanuele C; Fanelli GN; Fernandes B; Ferrara G; Gnetti L; Gurrera A; Leone G; Lucci R; Mancini C; Marangi G; Mastropasqua MG; Nibid L; Orrù S; Pastena M; Peresi M; Perracchio L; Santoro A; Vezzosi V; Zambelli C; Zuccalà V; Rizzo A; Costarelli L; Pietribiasi F; Santinelli A; Scatena C; Curigliano G; Guerini-Rocco E; Martini M; Graziano P; Castellano I; d'Amati G
    Crit Rev Oncol Hematol; 2023 Oct; 190():104103. PubMed ID: 37595344
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1 testing in metastatic triple-negative breast cancer: Interobserver and interplatform reproducibility of CE-IVD assays for CPS and IC scores.
    Ivanova M; Frascarelli C; Cerbelli B; Pignataro MG; Pernazza A; Venetis K; Sajjadi E; Criscitiello C; Curigliano G; Guerini-Rocco E; Graziano P; Martini M; d'Amati G; Fusco N
    Hum Pathol; 2024 Feb; 144():22-27. PubMed ID: 38278450
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Contribution of tumour and immune cells to PD-L1 expression as a predictive biomarker in metastatic triple-negative breast cancer: exploratory analysis from KEYNOTE-119.
    Cortes J; Winer EP; Lipatov O; Im SA; Gonçalves A; Muñoz-Couselo E; Lee KS; Schmid P; Tamura K; Testa L; Witzel I; Ohtani S; Hund S; Kulangara K; Karantza V; Mejia JA; Ma J; Jelinic P; Huang L; Pruitt SK; Emancipator K
    J Pathol Clin Res; 2024 May; 10(3):e12371. PubMed ID: 38627977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    Vainer G; Huang L; Emancipator K; Nuti S
    PLoS One; 2023; 18(6):e0285764. PubMed ID: 37267266
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of SP142 and 22C3 PD-L1 assays in a population-based cohort of triple-negative breast cancer patients in the context of their clinically established scoring algorithms.
    Sigurjonsdottir G; De Marchi T; Ehinger A; Hartman J; Bosch A; Staaf J; Killander F; Niméus E
    Breast Cancer Res; 2023 Oct; 25(1):123. PubMed ID: 37817263
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer.
    Noske A; Wagner DC; Schwamborn K; Foersch S; Steiger K; Kiechle M; Oettler D; Karapetyan S; Hapfelmeier A; Roth W; Weichert W
    Breast; 2021 Dec; 60():238-244. PubMed ID: 34768219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28-8 pharmDx assays for responses to immunotherapy.
    Ahn S; Kim KM
    Mod Pathol; 2021 Sep; 34(9):1719-1727. PubMed ID: 34002009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors.
    Marchetti A; Barberis M; Franco R; De Luca G; Pace MV; Staibano S; Volante M; Buttitta F; Guerini-Rocco E; Righi L; D'antuono T; Scagliotti GV; Pinto C; De Rosa G; Papotti M
    J Thorac Oncol; 2017 Nov; 12(11):1654-1663. PubMed ID: 28818609
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PD-L1 Expression Harmonization in Gastric Cancer Using 22C3 PharmDx and SP263 Assays.
    Dabbagh TZ; Sughayer MA
    Appl Immunohistochem Mol Morphol; 2021 Jul; 29(6):462-466. PubMed ID: 33480602
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of assessment of programmed death-ligand 1 (PD-L1) status in triple-negative breast cancer biopsies and surgical specimens.
    Noske A; Steiger K; Ballke S; Kiechle M; Oettler D; Roth W; Weichert W
    J Clin Pathol; 2024 Mar; 77(4):239-245. PubMed ID: 36669878
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining PD-L1 Status in Patients With Triple-Negative Breast Cancer: Lessons Learned From IMpassion130.
    Badve SS; Penault-Llorca F; Reis-Filho JS; Deurloo R; Siziopikou KP; D'Arrigo C; Viale G
    J Natl Cancer Inst; 2022 May; 114(5):664-675. PubMed ID: 34286340
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-L1 Testing in Gastric Cancer by the Combined Positive Score of the 22C3 PharmDx and SP263 Assay with Clinically Relevant Cut-offs.
    Park Y; Koh J; Na HY; Kwak Y; Lee KW; Ahn SH; Park DJ; Kim HH; Lee HS
    Cancer Res Treat; 2020 Jul; 52(3):661-670. PubMed ID: 32019283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluating programmed death-ligand 1 (PD-L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study.
    Cerbelli B; Girolami I; Eccher A; Costarelli L; Taccogna S; Scialpi R; Benevolo M; Lucante T; Luigi Alò P; Stella F; Gemma Pignataro M; Fadda G; Perrone G; D'Amati G; Martini M
    Histopathology; 2022 Jan; 80(2):397-406. PubMed ID: 34496080
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.
    Danziger N; Sokol ES; Graf RP; Hiemenz MC; Maule J; Parimi V; Palmieri C; Pusztai L; Ross JS; Huang RSP
    Oncologist; 2023 Apr; 28(4):319-326. PubMed ID: 36866462
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel-Treated Advanced Triple-Negative Breast Cancer.
    Rugo HS; Loi S; Adams S; Schmid P; Schneeweiss A; Barrios CH; Iwata H; Diéras V; Winer EP; Kockx MM; Peeters D; Chui SY; Lin JC; Nguyen-Duc A; Viale G; Molinero L; Emens LA
    J Natl Cancer Inst; 2021 Nov; 113(12):1733-1743. PubMed ID: 34097070
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discordance in PD-L1 expression using 22C3 and SP142 assays between primary and metastatic triple-negative breast cancer.
    Miyakoshi J; Yazaki S; Shimoi T; Onishi M; Saito A; Kita S; Yamamoto K; Kojima Y; Sumiyoshi-Okuma H; Nishikawa T; Sudo K; Noguchi E; Murata T; Shiino S; Takayama S; Suto A; Fujiwara Y; Yoshida M; Yonemori K
    Virchows Arch; 2023 Dec; 483(6):855-863. PubMed ID: 37668667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Harmonization of programmed death-ligand 1 immunohistochemistry and mRNA expression scoring in metastatic melanoma: a multicentre analysis.
    Darmon-Novello M; Adam J; Lamant L; Battistella M; Ortonne N; Balme B; de la Fouchardière A; Chaltiel L; Gerard E; Franchet C; Vergier B
    Histopathology; 2022 Jun; 80(7):1091-1101. PubMed ID: 35322452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of Surgical Pathologist for Detection of Predictive Immuno-oncological Factors in Breast Cancer.
    Berner M; Hartmann A; Erber R
    Adv Anat Pathol; 2023 May; 30(3):195-202. PubMed ID: 36418243
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications.
    Nuti S; Zhang Y; Zerrouki N; Roach C; Bänfer G; Kumar GL; Manna E; Diezko R; Kersch K; Rüschoff J; Jasani B
    Histopathology; 2022 Dec; 81(6):732-741. PubMed ID: 35993150
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplex immunohistochemistry/immunofluorescence (mIHC/IF) for PD-L1 testing in triple-negative breast cancer: a translational assay compared with conventional IHC.
    Yeong J; Tan T; Chow ZL; Cheng Q; Lee B; Seet A; Lim JX; Lim JCT; Ong CCH; Thike AA; Saraf S; Tan BYC; Poh YC; Yee S; Liu J; Lim E; Iqbal J; Dent R; Tan PH
    J Clin Pathol; 2020 Sep; 73(9):557-562. PubMed ID: 31969377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.